Pogust Goodhead is currently litigating against the manufacturers of EzriCare and Delsam Pharma’s Artificial Tears in the US, and, this week, the Wall Street Journal has published a feature on the lawsuit and our client, Beverly Jennings.
Beverly lost vision in her right eye after using the EzriCare Artificial Tears that she bought on Amazon last April. The product was manufactured in India by Global Pharma.
According to the Centers for Disease Control and Prevention and the Journal’s recent article, at least four people have died due to a bacterial outbreak linked to Ezricare and Delsam Pharma’s contaminated eye drops, which were made by India-based Global Pharma Healthcare.
It is reported that more than 80 people in 18 states across the US have been infected by the artificial tears.
Mike Daly, Partner at Pogust Goodhead, said: “Bev is suffering through a devastating and permanent injury. Thankfully, she is a remarkably strong woman who is making adjustments to cope with her new condition, but we suspect the trauma, fear, and pain caused by these contaminated eye drops will endure for some time.”
India’s $50 billion pharmaceutical industry has a poor safety record. The Food and Drug Administration told the US Congress in 2019 that Indian drugmakers had the lowest rate of acceptable inspection outcomes among some 90 countries.
About 83% of factories in India met safety and quality standards, the FDA said, compared with 90% in China and 93% in the U.S.
Pogust Goodhead is taking Global Pharma, EzriCare, and Amazon to court in New Jersey. We will also be filing on behalf of numerous other individuals from around the US who suffered horrific vision loss and damage to their eyes. For more information on the claim, head to myezricareclaim.com.
As a global law firm, we are committed to litigating these cases in the US and have begun pursuing potential new claims for individuals in similar circumstances all across the world, as similar catastrophes caused by manufacturing facilities in India have also wreaked havoc on children and communities in Indonesia, Gambia, and elsewhere.
You can read the full article from the WSJ here.